You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR 1-4

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

FGFR Testing by Either ctDNA Blood Testing or Standard Tumor

Recruiting
  • Metastatic Bladder Cancer
  • Metastatic Urothelial Carcinoma
  • FGFR Testing
  • Calgary, Alberta, Canada
  • +6 more
Nov 8, 2023

Cancer Trial in St. Gallen (Rogaratinib (BAY1163877), Combination drug)

Completed
  • Cancer
  • Rogaratinib (BAY1163877)
  • Combination drug
  • St. Gallen, Sankt Gallen, Switzerland
    Kantonsspital St. Gallen
Mar 20, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in

Recruiting
  • Locally Advanced Gastrointestinal Stromal Tumor
  • +7 more
  • Biopsy
  • +4 more
  • Duarte, California
  • +17 more
Feb 2, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)

Active, not recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023

Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)

Recruiting
  • Gastrointestinal Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Dec 7, 2022

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter Trial in Spain, United States (PRN1371)

Terminated
  • Solid Tumors
  • Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
  • San Francisco, California
  • +11 more
Dec 23, 2020

Solid Tumor Trial in Worldwide (Debio 1347)

Terminated
  • Solid Tumor
  • Debio 1347
  • Scottsdale, Arizona
  • +104 more
Mar 30, 2022

Advanced Solid Tumors Trial in Beijing (EVER4010001)

Recruiting
  • Advanced Solid Tumors
  • Beijing, Beijing, China
    Department of Gastrointestinal Oncology, the Fifth Medical Cente
Jan 5, 2021

Cholangiocarcinoma Trial in Worldwide (Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice)

Not yet recruiting
  • Cholangiocarcinoma
  • Tinengotinib 8 mg
  • +2 more
  • Santa Monica, California
  • +13 more
Jul 7, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))

Completed
  • Advanced or Metastatic Solid Tumor
  • Rogaratinib (BAY1163877)
  • Copanlisib (BAY80-6946)
  • Los Angeles, California
  • +19 more
Jul 13, 2022

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors Trial in

Active, not recruiting
  • Cholangiocarcinoma
  • +5 more
  • Gilbert, Arizona
  • +57 more
Jan 5, 2022

Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy Trial in Arlington Heights (Panzyga IVIG,

Not yet recruiting
  • Small Fiber Neuropathy
  • +3 more
  • Panzyga IVIG
  • Placebo
  • Arlington Heights, Illinois
    Northwest Community Healthcare
Aug 22, 2022

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation
  • Gilbert, Arizona
  • +115 more
Oct 17, 2022

Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma Trial in Worldwide (derazantinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Combined Hepatocellular and Cholangiocarcinoma
  • Phoenix, Arizona
  • +40 more
Mar 7, 2022

Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose

Completed
Has Results
  • Solid Tumor
  • Derazantinib low dose range
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Mar 7, 2022

Advanced Non Small Cell Lung Cancer Trial (Sintilimab, Pemigatinib)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Aug 6, 2021